Log in

NASDAQ:NVUS - Novus Therapeutics Stock Price, Forecast & News

$0.52
+0.01 (+1.96 %)
(As of 02/21/2020 04:00 PM ET)
Today's Range
$0.49
Now: $0.52
$0.53
50-Day Range
$0.48
MA: $0.62
$0.95
52-Week Range
$0.40
Now: $0.52
$5.21
Volume141,362 shs
Average Volume399,683 shs
Market Capitalization$6.74 million
P/E RatioN/A
Dividend YieldN/A
Beta2.84
Novus Therapeutics, Inc, a pharmaceutical company, focuses on developing products for patients with disorders of ear, nose, and throat. Its lead product is (OP-02), a surfactant-based combination drug product for patients at risk for, or with, otitis media (OM) (middle ear inflammation with or without infection). The company also has a foam-based drug delivery technology (OP-01) that could be used to deliver drugs into the ear, nose, and sinus cavities. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NVUS
CUSIPN/A
Phone949-238-8090

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.54 per share

Profitability

Net Income$-14,060,000.00

Miscellaneous

EmployeesN/A
Market Cap$6.74 million
Next Earnings Date3/26/2020 (Estimated)
OptionableNot Optionable

Receive NVUS News and Ratings via Email

Sign-up to receive the latest news and ratings for NVUS and its competitors with MarketBeat's FREE daily newsletter.


Novus Therapeutics (NASDAQ:NVUS) Frequently Asked Questions

What is Novus Therapeutics' stock symbol?

Novus Therapeutics trades on the NASDAQ under the ticker symbol "NVUS."

How were Novus Therapeutics' earnings last quarter?

Novus Therapeutics Inc (NASDAQ:NVUS) released its quarterly earnings results on Wednesday, November, 13th. The biopharmaceutical company reported ($0.22) earnings per share for the quarter, beating analysts' consensus estimates of ($0.41) by $0.19. View Novus Therapeutics' Earnings History.

When is Novus Therapeutics' next earnings date?

Novus Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March 26th 2020. View Earnings Estimates for Novus Therapeutics.

What price target have analysts set for NVUS?

2 equities research analysts have issued 12-month price objectives for Novus Therapeutics' shares. Their forecasts range from $2.00 to $10.00. On average, they expect Novus Therapeutics' share price to reach $6.00 in the next year. This suggests a possible upside of 1,053.8% from the stock's current price. View Analyst Price Targets for Novus Therapeutics.

What is the consensus analysts' recommendation for Novus Therapeutics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novus Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Novus Therapeutics.

Has Novus Therapeutics been receiving favorable news coverage?

Headlines about NVUS stock have trended somewhat positive recently, according to InfoTrie Sentiment. InfoTrie rates the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Novus Therapeutics earned a media sentiment score of 1.3 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Novus Therapeutics.

Are investors shorting Novus Therapeutics?

Novus Therapeutics saw a decrease in short interest in the month of January. As of January 31st, there was short interest totalling 19,500 shares, a decrease of 67.5% from the January 15th total of 60,000 shares. Based on an average daily volume of 125,000 shares, the days-to-cover ratio is currently 0.2 days. Currently, 0.2% of the company's stock are sold short. View Novus Therapeutics' Current Options Chain.

Who are some of Novus Therapeutics' key competitors?

What other stocks do shareholders of Novus Therapeutics own?

Who are Novus Therapeutics' key executives?

Novus Therapeutics' management team includes the folowing people:
  • Mr. Gregory J. Flesher, CEO & Director (Age 49)
  • Dr. Catherine C. Turkel, Pres (Age 58)
  • Mr. Jon Kuwahara CPA, Sr. VP of Fin. & Admin. (Age 54)

Who are Novus Therapeutics' major shareholders?

Novus Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (3.51%). Company insiders that own Novus Therapeutics stock include Catherine C Turkel, Erez Chimovits, Gregory J Flesher, Jon Kuwahara and Lifesci Index Partners Llc. View Institutional Ownership Trends for Novus Therapeutics.

Which major investors are buying Novus Therapeutics stock?

NVUS stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. Company insiders that have bought Novus Therapeutics stock in the last two years include Catherine C Turkel and Erez Chimovits. View Insider Buying and Selling for Novus Therapeutics.

How do I buy shares of Novus Therapeutics?

Shares of NVUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Novus Therapeutics' stock price today?

One share of NVUS stock can currently be purchased for approximately $0.52.

How big of a company is Novus Therapeutics?

Novus Therapeutics has a market capitalization of $6.74 million. The biopharmaceutical company earns $-14,060,000.00 in net income (profit) each year or ($1.56) on an earnings per share basis. View Additional Information About Novus Therapeutics.

What is Novus Therapeutics' official website?

The official website for Novus Therapeutics is http://novustherapeutics.com/.

How can I contact Novus Therapeutics?

Novus Therapeutics' mailing address is 19900 MACARTHUR BLVD. SUITE 550, IRVINE CA, 92612. The biopharmaceutical company can be reached via phone at 949-238-8090 or via email at [email protected]


MarketBeat Community Rating for Novus Therapeutics (NASDAQ NVUS)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  234 (Vote Outperform)
Underperform Votes:  226 (Vote Underperform)
Total Votes:  460
MarketBeat's community ratings are surveys of what our community members think about Novus Therapeutics and other stocks. Vote "Outperform" if you believe NVUS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVUS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/22/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel